Research is ongoing to enhance the GVT effect while minimizing the risk of GVHD. Strategies include: 1. Donor Selection: Choosing donors with specific [human leukocyte antigen (HLA)]( ) matches can reduce GVHD risk. 2. Cellular Therapies: The use of [engineered T cells]( ) or NK cells that are designed to target cancer cells more specifically. 3. Cytokine Modulation: Administering cytokines that boost the GVT effect without exacerbating GVHD. 4. Immune Checkpoint Inhibitors: These drugs can enhance the anti-tumor activity of donor immune cells while potentially reducing GVHD.
